News

   

Asarina Pharma: Journal of Neuroendocrinology publishes preclinical data on effective Tourette syndrome therapy with no side effects

Stockholm, June 12 2019: A new paper in the Journal of Neuroendocrinology shows how Asarina Pharma’s compound Sepranolone reduced tics in an animal model of Tourette syndrome as effectively as current first-line treatment Haldol—without inducing any motor side effects.

Full PDF
   

Premenstrual Dysphoric Disorder recognized in new WHO International Classification of Diseases ICD-11

Stockholm, June 11, 2019: Premenstrual dysphoric disorder (PMDD) has been given its own classification code and for the first time classified clearly as a gynaecological, not mental, disease in the WHO’s new International Classification of Diseases, ICD-11. “This is a crucial step forward for future diagnosis, treatment and reimbursement of our lead indication” says CEO…

Full PDF
   

PMS & PMDD in spotlight at Gothenburg event for International Menstrual Hygiene Day

(Stockholm May 23, 2019) Valuable knowledge about PMS & PMDD will be shared at the University of Gothenburg on May 28 at a public evening of talks, lectures and Q&A. Prof Torbjörn Bäckström, PMDD research pioneer and Asarina Pharma CSO, will speak about the science and treatment of PMDD.

Full PDF
   

Decisions from Annual General Meeting of Asarina Pharma, 8 May 2019

(Stockholm May 8, 2019) On 8 May 2019, the Annual General Meeting (”AGM”) of Asarina Pharma AB (publ) was held in Stockholm. Read below for a summary of the decisions made.

Full PDF
   

Asarina Pharma Clinical Trial featured on BBC

(Stockholm April 23 2019) With approx. 4 million listeners, on April 17 BBC Radio’s iconic programme ‘Woman’s Hour’ highlighted the clinical trial of a new treatment for PMDD, the severest form of PMS. The trial is being carried out by Swedish company Asarina Pharma

Full PDF
   

Asarina Pharma Scientific Advisory Board gives full backing to Menstrual Migraine Phase IIA trial

Stockholm – December 18, 2018. On December 17 Asarina Pharma’s Scientific Advisory Board (SAB) gave its full backing to the company’s upcoming trial of a new preventive treatment for Menstrual Migraine. The SAB comprises world-leading independent scientists in obstetrics, gynaecology, neurology and pharmacology, including Prof Anne MacGregor, one of the world’s foremost authorities on headache…

Full PDF
   

Asarina Pharma CSO presents at PMS event in Stockholm: ‘It’s time to talk about PMDD’

Torbjörn Bäckström, Asarina Pharma CSO, and Karin Ekberg, COO, spoke at PMS & PMDD Day on November 21, at Medelhavsmuseet, Stockholm. A wide range of PMS researchers, educators and activists took part. “It’s fantastic to see this billed as PMS and PMDD Day,” says Asarina Pharma CEO Peter Nordkild. “It shows how much knowledge of…

Full PDF
   

Asarina Pharma sponsors PMS Day Stockholm ‘Women’s health affects all of us, it’s time to talk about PMDD’

Stockholm – October 23, 2018. Asarina Pharma is sponsoring 2018’s PMS Day in Stockholm on November 21. Sharing knowledge on all aspects of PMS and PMDD, the event includes cultural celebrities like Paula Fenjima Manrique and Lisa Stenberg, as well as leading scientists like Asarina Pharma’s own PMDD pioneer, Prof. Törbjörn Bäckström. CEO Peter Nordkild:…

Full PDF
   

Asarina Pharma sponsrar PMS-dagen i Stockholm. ”Kvinnors hälsa påverkar oss alla, det är hög tid börja prata om PMDS”.

Stockholm – 23 oktober, 2018. Asarina Pharma sponsrar PMS-dagen i Stockholm den 21 november. Evenemanget kommer att handla om olika aspekter av PMS och PMDS och gästas av kulturpersonligheter som Paula Fenjima Manrique och Lisa Eriksson samt ledande forskare, bland annat Asarina Pharmas egen PMDS-pionjär, professor Torbjörn Bäckström. – Kvinnors hälsa påverkar var och en…

Full PDF
   

Asarina Pharma sponsrar PMS-dagen i Stockholm. ”Kvinnors hälsa påverkar oss alla, det är hög tid börja prata om PMDS”.

Stockholm – 23 oktober, 2018. Asarina Pharma sponsrar PMS-dagen i Stockholm den 21 november. Evenemanget kommer att handla om olika aspekter av PMS och PMDS och gästas av kulturpersonligheter som Paula Fenjima Manrique och Lisa Stenberg samt ledande forskare, bland annat Asarina Pharmas egen PMDS-pionjär, professor Torbjörn Bäckström. – Kvinnors hälsa påverkar var och en…

Full PDF
   

Hilfe gegen die schwerste Form von PMS: Einzigartige Studie in Deutschland startet.

Die prämenstruelle dysphorische Störung (PMDS), die schwerste Form prämenstrueller Störungen (PMS), ist eine oft bagatellisierte Krankheit in Zusammenhang mit dem weiblichen Monatszyklus. Bei manchen Frauen sind die Beschwerden so stark ausgeprägt, dass sie sich mit Selbstmordgedanken tragen. Doch Hilfe ist in Sicht: Das erste Medikament gegen PMDS ist auf dem Weg zur Zulassung. Das innovative…

Full PDF
   

Z pomocą przeciw najcięższej formie PMS – Polki pierwsze w unikalnych badaniach

PMDD, najcięższa forma PMS, to ukryta choroba kobieca, która każdego miesiąca przysparza dużo udręki. Niektóre kobiety cierpią przed miesiączką na tak ciężkie dolegliwości, że mają myśli samobójcze. Teraz jednak pierwszy lek przeciwko PMDD może stać się rzeczywistością. Innowacyjna szwedzka spółka Asarina Pharma w zakrojonych na szeroką skalę europejskich badaniach klinicznych daje Polkom możliwość stać się…

Full PDF
   

Asarina Pharma: sharp rise on first day of trading on Nasdaq First North

After 40 years’ of research developing its breakthrough PMDD treatment Sepranolone, Asarina Pharma hit the ground running on Monday 24 September as it launched on Nasdaq First North in Stockholm. With major institutions getting behind the research—how did the successful market launch feel for the scientific and business team at Asarina Pharma?

Full PDF
   

Nasdaq Stockholm Welcomes Asarina Pharma to First North

Stockholm, September 24, 2018— Nasdaq (Nasdaq: NDAQ) today announced that trading in Asarina Pharma AB’s shares (short name: ASAP) commences today on Nasdaq First North in Stockholm. Read Nasdaq First North's Press Release below, or HERE.  (https://globenewswire.com/news-release/2018/09/24/1574651/0/en/Nasdaq-Stockholm-Welcomes-Asarina-Pharma-to-First-North.html)

   

Asarina Pharma IPO oversubscribed 175%: CEO welcomes new shareholders

With its IPO listing oversubscribed by 175%, Asarina Pharma is firmly in the investor and scientific spotlight. Here, CEO Peter Nordkild shares upcoming research and business highlights with the company’s new shareholders.

Full PDF
   

Asarina Pharma AB (publ) har erhållit godkännande för listning av bolagets aktier på Nasdaq First North

Nasdaq har godkänt Asarina Pharma AB (publ) (”Asarina Pharma” eller ”Bolaget”) för listning på Nasdaq First North. Första dag för handel i Bolagets aktier är måndag den 24 september 2018.

Full PDF
   

Asarina Pharma AB (publ) has received approval for listing of the company’s shares on Nasdaq First North

Nasdaq has approved Asarina Pharma AB (publ) (”Asarina Pharma” or the “Company”) for listing on Nasdaq First North. First day of trading in the Company’s shares is on Monday, 24 September, 2018.

Full PDF
   

Nyemissionen i Asarina Pharma AB (publ) inför notering på First North övertecknad

Den 24 augusti 2018 beslutade styrelsen i Asarina Pharma AB (publ) (”Asarina Pharma” eller ”Bolaget”), med stöd av bemyndigande från extra bolagstämman den 28 juni 2018, att genomföra en nyemission om högst 6 800 000 aktier (”Erbjudandet”) och ansöka om listning av Bolagets aktier på Nasdaq First North. Första dag för handel är planerad till den 24…

Full PDF
   

Share issue in Asarina Pharma AB (publ) oversubscribed before listing on First North

On 24 August 2018, the Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”), resolved, with the authorization from the Extraordinary General Meeting on 28 June, 2018, on a share issue of up to 6,800,000 shares (the “Offer”) and to apply for admission to trading of the Company’s share on Nasdaq…

Full PDF
   

Asarina Pharma in på börsen – träffar investerare i Göteborg och Stockholm

Asarina Pharmas ansökan om notering av på Nasdaq First North den 28 augusti har redan väckt stort intresse. På tisdag den 4 september presenterar bolaget sitt erbjudande på Aktiekvällen i Göteborg och därefter följer flera investerarevent i Stockholm.

Full PDF
   

Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm

On August 28 Asarina Pharma applied to be listed on Nasdaq First North, generating significant interest. On Tuesday, September 4 the company presents to investors at Aktiekvällen in Gothenburg, followed by further events in Stockholm.

Full PDF
   

Asarina Pharma AB offentliggör prospekt i samband med nyemission om 142,8 MSEK inför notering på Nasdaq First North

Styrelsen i Asarina Pharma AB (”Asarina Pharma” eller ”Bolaget”) har beslutat att genomföra en nyemission om högst 6 800 000 aktier samt notera Bolagets aktier på Nasdaq First North. Teckningskursen uppgår till 21 SEK per aktie, vilket motsvarar ett emissionsbelopp om högst 142,8 MSEK (”Erbjudandet”). Baserat på emissionskursen och befintligt antal aktier värderas Bolaget till omkring 172…

Full PDF
   

Asarina Pharma AB publishes prospectus in connection with share issue of SEK 142,8M and listing on Nasdaq First North

The Board of Asarina Pharma AB (“Asarina Pharma” or the “Company”) has resolved on a share issue of up to 6,800,000 shares and has decided to apply for admission to trading of the Company’s share on Nasdaq First North. The subscription price amounts to SEK 21 per share, which corresponds to an issue amount of…

Full PDF
   

Chief Medical Officer appointed for clinical trials of world’s first therapy targeting both PMDD and menstrual migraine

Stockholm – June 29, 2018. A small Swedish pharmaceutical company has taken another step towards being the first company in the world to launch a targeted treatment for PMDD—the most debilitating form of PMS. Dr Märta Segerdahl has been appointed Chief Medical Officer, with over 20 years’ experience in pain medicine, including menstrual migraine.

Full PDF
   

Asarina Pharma: New cross-border Board reflects global potential of therapy

Stockholm – May 31, 2018. Asarina Pharma’s new Board reflects the global potential of its first-in-class therapy for PMDD. New members include senior pharma, science and research professionals from a range of countries contributing a powerful mix of skills.

Full PDF
   

Asarina Pharma: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD

Stockholm – April 24, 2018. The first patients arrived in clinics in Krakow, Poland and Berlin, Germany to take part in Phase IIB trials of the world’s first treatment for PMDD. CEO Peter Nordkild: “This is a milestone moment. Already having patients in the clinic, only ten days after the study opened, underlines the powerful…

Full PDF
   

Asarina Pharma: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD

Stockholm – April 24, 2018. The first patients arrived in clinics in Krakow, Poland and Berlin, Germany to take part in Phase IIB trials of the world’s first treatment for PMDD. CEO Peter Nordkild: “This is a milestone moment. Already having patients in the clinic, only ten days after the study opened, underlines the powerful…

Full PDF
   

Asarina Pharma Phase IIB Study receives surge in applicants volunteering for new PMDD treatment—on its first day live

Stockholm – April 16, 2018. In just one day 29 patients passed the first screening stage of the trial for the world’s first PMDD therapy. Asarina Pharma CEO Peter Nordkild: “This reflects the desperate need for a dedicated therapy for this devastating form of PMS—and the huge market potential.”  

Full PDF
   

Asarina Pharma recruits patients for Phase IIB trial of Sepranolone, world’s first treatment targeting PMDD, premenstrual dysphoric disorder

Patient enrolment is expected to be high for the Phase IIB clinical trial of Sepranolone, driven by strong medical need for a therapy that specifically targets PMDD, the severest form of PMS, in a market with few alternatives. Patients will be recruited in UK, Poland, Germany and Sweden.

Full PDF